Last updated: October 17, 2026
YCANTH, Verrica Pharmaceuticals' cantharidin 0.7% topical solution, is the first FDA-approved treatment for molluscum contagiosum. FDA approval on July 21, 2023 created a regulated commercial category from a previously compounded therapy market. Early commercial performance depends on physician adoption, reimbursement, dermatology-channel access, and the conversion of office-based treatments to prescription dispensing. The product has no biosimilar risk, but generic competition remains a long-term threat because cantharidin is an old active ingredient and the product is a topical small-molecule drug.
What is YCANTH and what market does it address?
YCANTH is a topical solution containing 0.7% cantharidin in a single-use applicator. It is indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients two years of age and older. Healthcare professionals apply the product in the office and wash it off after a defined exposure period. Patients do not self-apply the product at home because cantharidin can injure unaffected skin and mucous membranes.
Molluscum contagiosum is a contagious viral skin infection caused by a poxvirus. It is common in children, although adults can also develop the disease. Before YCANTH, treatment options included observation, cryotherapy, curettage, blistering agents, and compounded cantharidin. These alternatives had inconsistent reimbursement and varied substantially by physician practice.
The commercial opportunity has four defining characteristics:
| Market factor |
YCANTH implication |
| Disease prevalence |
Broad pediatric patient pool, but many cases resolve without treatment |
| Treatment setting |
Dermatology, pediatrics, family practice, and urgent-care offices |
| Product administration |
Office-applied, which limits pharmacy substitution but creates workflow requirements |
| Prior standard of care |
Compounded cantharidin and procedural treatment create established alternatives |
Verrica has positioned YCANTH as a standardized, FDA-reviewed alternative to compounded cantharidin. The company has also emphasized single-use packaging, controlled concentration, and a defined application process as commercial differentiators.
How large is the YCANTH addressable market?
The addressable market is larger than the near-term reimbursed market. Molluscum is common, but not every patient receives prescription treatment, and some physicians continue to use observation or office procedures.
Verrica has described a U.S. patient population of several million children with molluscum contagiosum. The practical commercial market is narrower because treatment is concentrated among patients with persistent, extensive, symptomatic, cosmetically concerning, or socially disruptive lesions.
The most attractive initial segments are:
- Pediatric dermatology practices with high patient throughput.
- General dermatology practices already treating pediatric skin conditions.
- Pediatricians who previously referred patients to dermatologists.
- Patients with multiple lesions requiring repeated procedures.
- Families seeking an FDA-approved treatment instead of watchful waiting.
YCANTH's market penetration is constrained by three factors. First, molluscum is often self-limited. Second, many payers historically treated cantharidin as a noncovered compounded or procedural therapy. Third, office application creates a staffing and scheduling burden that does not exist with conventional retail prescriptions.
What is the FDA regulatory status of YCANTH?
YCANTH was approved by the FDA on July 21, 2023, under NDA 214701 for molluscum contagiosum in adults and pediatric patients two years and older.[1]
| Regulatory event |
Date |
| FDA approval |
July 21, 2023 |
| Approved indication |
Topical treatment of molluscum contagiosum |
| Minimum approved age |
Two years |
| Dosage form |
Topical solution, 0.7% cantharidin |
| Administration |
Healthcare-professional application |
| Regulatory pathway |
New drug application |
The approval converted cantharidin from a largely compounding-based treatment into an FDA-approved prescription product. It also gives Verrica a regulatory reference point for future lifecycle development, including pediatric expansion, additional dermatologic indications, and alternative delivery formats.
The approval does not eliminate competition from compounded products. Compounding pharmacies may continue to compete where legally permitted, particularly when prescribers or payers resist branded product pricing. The commercial distinction is that YCANTH has FDA-reviewed manufacturing, labeling, concentration, packaging, and safety information.
What patents protect YCANTH?
YCANTH's protection is based primarily on formulation, delivery, packaging, and method-of-use claims rather than ownership of cantharidin itself. Cantharidin is an old natural-product active ingredient, which limits the value of composition-of-matter protection.
Verrica's patent portfolio has included U.S. patents directed to cantharidin formulations and methods of treating molluscum contagiosum. Public patent records identify issued patents in the YCANTH portfolio, including U.S. Patent No. 11,771,682. The relevant protection focuses on the pharmaceutical composition, topical application, and treatment method rather than a new molecular entity.
| Protection category |
Commercial relevance |
| Cantharidin active ingredient |
Weak standalone protection because the ingredient is old |
| Concentration and excipient system |
Can create formulation differentiation |
| Single-use applicator |
May create device, packaging, and safety barriers |
| Office-application method |
Can support method-of-use infringement claims |
| Manufacturing process |
Can raise quality and reproducibility barriers |
| FDA exclusivity |
Delays certain abbreviated applications independent of patent validity |
Patent term and Orange Book listing status must be evaluated patent by patent. FDA Orange Book listings, USPTO records, terminal disclaimers, patent-term adjustments, and any pediatric extension determine the practical end date for each listed patent.[2,3]
What is the Orange Book status of YCANTH?
YCANTH is an approved prescription drug under NDA 214701. Verrica has pursued patent protection for the product and its underlying formulation technology. The commercial importance of Orange Book listings is that an ANDA applicant may need to certify against listed patents under Paragraph I, II, III, or IV.
A Paragraph IV certification would allege that a listed patent is invalid, unenforceable, or not infringed. If Verrica sues within 45 days, the FDA may apply a 30-month stay to final ANDA approval, subject to statutory exceptions and litigation developments.[4]
The principal regulatory risk is not a biosimilar filing. YCANTH is a small-molecule topical drug, so the relevant future challenge would be an ANDA or another abbreviated pathway, not a biosimilar application under the Public Health Service Act.
When does YCANTH lose exclusivity?
YCANTH's effective exclusivity has several layers:
| Exclusivity layer |
Expected effect |
| FDA approval exclusivity |
Blocks certain abbreviated applications for the applicable statutory period |
| Orange Book patents |
May delay generic approval until patent expiry or successful challenge |
| Formulation know-how |
Can make equivalent product development more difficult |
| Device and packaging implementation |
May complicate direct substitution |
| Trademark and brand recognition |
Supports post-generic commercial retention but does not block approval |
The precise loss-of-exclusivity date depends on the FDA exclusivity code and current Orange Book records. A 3-year exclusivity period, if applicable to the approval's qualifying clinical investigations, would expire in July 2026. Patent protection could extend beyond that point if valid listed patents remain in force.
Because cantharidin itself is not a newly discovered active molecule, YCANTH does not have the same protection profile as a conventional new chemical entity with a strong composition-of-matter patent. Its value depends on the durability of the formulation and method claims.
How strong is the YCANTH patent estate?
The estate is commercially meaningful but not structurally comparable to a protected novel molecule. Its strengths are:
- FDA-approved formulation and concentration.
- Controlled product presentation.
- Clinical and manufacturing data.
- Office-application instructions.
- Potential patent protection covering formulation and use.
- First-mover status in an FDA-approved category.
Its weaknesses are:
- Cantharidin is an established active ingredient.
- Compounded cantharidin provides an alternative treatment channel.
- Generic developers may design around formulation claims.
- Method-of-use enforcement can be difficult when infringement depends on physician behavior.
- Topical products can face bioequivalence and pharmaceutical-equivalence questions that differ from oral generics.
The strongest commercial barrier is likely the combination of regulatory approval, physician familiarity, reimbursement infrastructure, and manufacturing consistency. Patent protection alone is less decisive than it would be for a patented molecular entity.
What is the financial trajectory for YCANTH?
Verrica began commercializing YCANTH in the second half of 2023. The launch period required investment in sales personnel, market access, distribution, patient support, and physician education. Revenue growth therefore needs to be assessed against launch costs rather than product sales alone.
Public company filings report that YCANTH generated initial product revenue in 2023 after launch, followed by materially higher revenue as distribution and prescribing expanded in 2024.[5] The financial trajectory has the following stages:
| Period |
Commercial condition |
Financial implication |
| 2023 launch |
Initial stocking, limited awareness, reimbursement buildout |
Low starting revenue and high selling expense |
| 2024 expansion |
Broader physician coverage and repeat prescribing |
Revenue acceleration and improved operating leverage |
| 2025 onward |
Penetration, payer normalization, and geographic expansion |
Greater predictability, but higher exposure to gross-to-net pressure |
| Post-exclusivity |
Potential ANDA or formulation competition |
Price and volume risk |
The core revenue equation is:
Revenue = treated patients × applications per patient × net price per treatment
YCANTH can generate repeat revenue because many patients require treatment of multiple lesions or more than one application cycle. The same characteristic can increase payer scrutiny because a single patient may require multiple units in one episode of care.
The main financial variables are:
- Number of active prescribing practices.
- Average units used per office visit.
- Re-treatment rates.
- Gross-to-net deductions.
- Commercial insurance coverage.
- Medicaid coverage and state policy.
- Patient abandonment at the pharmacy.
- Use of bridge, copay, and free-product programs.
- Sales-force productivity.
- Cost of goods and packaging.
A strong launch does not automatically produce strong operating income. Verrica must fund commercial infrastructure while building demand in a condition that is often observed rather than treated. The product's financial inflection point depends on whether revenue growth exceeds sales, marketing, patient-support, and manufacturing costs.
What reimbursement and pricing risks affect YCANTH?
YCANTH is exposed to reimbursement risk because molluscum contagiosum has historically been treated with low-cost procedures, compounded products, or no intervention. Commercial payers may impose prior authorization, quantity limits, specialty-pharmacy requirements, or medical-benefit restrictions.
The office-applied model creates a billing question. A practice may obtain YCANTH through a pharmacy channel, buy and bill it under a medical benefit, or use a specialty distribution arrangement. Each model affects inventory risk, working capital, reimbursement timing, and physician adoption.
Pricing pressure can arise from:
- Compounded cantharidin.
- Cryotherapy and curettage.
- Patient refusal to pay out of pocket.
- Payer classification as cosmetic or nonessential treatment.
- Future generic formulations.
- Reimbursement limits based on lesion count or treatment frequency.
Verrica's commercial strategy therefore depends on demonstrating that YCANTH reduces treatment friction, improves standardization, and gives practices a reimbursable FDA-approved product.
Which companies are challenging YCANTH?
No major biosimilar threat applies because YCANTH is a small-molecule topical drug. The competitive field consists of:
| Competitor |
Category |
Risk to YCANTH |
| Compounded cantharidin |
Pharmacy-compounded active ingredient |
High near-term substitution risk where permitted |
| Cryotherapy |
Office procedure |
High for limited lesions |
| Curettage |
Office procedure |
Moderate to high, depending on patient age and physician preference |
| Observation |
No active treatment |
High because molluscum often resolves naturally |
| Future ANDA products |
Generic topical cantharidin |
Long-term price and access risk |
| Other topical agents |
Off-label or investigational treatments |
Potential lifecycle and category risk |
The closest practical competitor is compounded cantharidin, not a branded pharmaceutical product. YCANTH must justify its premium through product consistency, FDA approval, physician convenience, safety controls, and reimbursement.
What licensing deals and manufacturing barriers affect YCANTH?
YCANTH's commercial value is concentrated at Verrica rather than distributed across a large partner network. Public disclosures have emphasized Verrica's commercialization activities and external manufacturing and supply arrangements rather than a major global pharmaceutical co-commercialization transaction.
Manufacturing barriers include:
- Consistent cantharidin concentration.
- Control of topical formulation properties.
- Single-use packaging.
- Stability and shelf-life.
- Protection against accidental exposure.
- Batch testing and quality release.
- Reliable supply of a natural-product active ingredient.
These barriers can deter casual compounding but are unlikely to prevent a well-capitalized generic manufacturer from developing a competing product if market economics support an ANDA.
What generic launch scenarios exist for YCANTH?
Three scenarios are commercially relevant.
Early Paragraph IV challenge
A generic applicant challenges the listed patents before full patent expiry. Verrica may sue, potentially triggering a 30-month stay. The outcome would depend on claim construction, formulation equivalence, infringement evidence, and patent validity.
Delayed generic entry
A generic applicant waits for the relevant exclusivity period to expire but designs around remaining formulation claims. This reduces litigation expense but may produce a product with different packaging, excipients, or administration instructions.
Compounded-product persistence
Compounded cantharidin remains the principal competitor even without an approved generic. This scenario can limit pricing power and slow market penetration, especially among practices with established compounding relationships.
How does YCANTH compare with other dermatology launches?
YCANTH has a narrower disease market than large dermatology drugs but a simpler competitive message. It does not compete against multiple branded immunomodulators or biologics for the same indication. Its challenge is treatment behavior: physicians may choose no treatment, a procedure, or a compounded product.
Compared with a patented chronic dermatology drug, YCANTH has:
| Dimension |
YCANTH |
| Disease duration |
Often self-limited |
| Treatment frequency |
Episodic, with possible repeat applications |
| Patient population |
Primarily pediatric |
| Administration |
Office-based |
| Generic risk |
Meaningful after regulatory and patent barriers |
| Biosimilar risk |
None |
| Reimbursement sensitivity |
High |
| Sales-force model |
Targeted dermatology and pediatric coverage |
Key Takeaways
- YCANTH is the first FDA-approved cantharidin product for molluscum contagiosum.
- FDA approval occurred on July 21, 2023, under NDA 214701.
- The market is commercially attractive but constrained by spontaneous disease resolution, procedural alternatives, compounded cantharidin, and reimbursement friction.
- Revenue growth depends on physician adoption, treated-patient volume, repeat applications, and payer coverage.
- YCANTH has formulation, method-of-use, packaging, and manufacturing protection, but not a strong new-molecule composition-of-matter position.
- The relevant future challenge is generic ANDA competition, not biosimilar competition.
- A Paragraph IV challenge could create litigation and delay generic approval through the statutory 30-month stay.
- Compounded cantharidin is the most important near-term competitive substitute.
- The financial trajectory can improve rapidly during physician and payer expansion, but operating leverage depends on whether commercial revenue outpaces launch costs.
- Patent and regulatory exclusivity should be analyzed together because the active ingredient itself is old and formulation design-around risk remains material.
FAQs
Is YCANTH a biologic or a small-molecule drug?
YCANTH is a small-molecule topical drug containing cantharidin. It is not a biologic and is not subject to biosimilar competition.
Can pharmacies compound a YCANTH equivalent?
Pharmacies may compound cantharidin products where permitted under applicable federal and state law. A compounded product is not the same as an FDA-approved YCANTH equivalent and may differ in formulation, quality controls, packaging, labeling, and evidence.
Does YCANTH have orphan-drug exclusivity?
YCANTH is approved for molluscum contagiosum and is not generally treated as an orphan-drug product. Its commercial protection comes from FDA approval exclusivity, patents, formulation know-how, and market adoption.
How is YCANTH administered?
A healthcare professional applies YCANTH to molluscum lesions in an office setting. The product is not intended for patient self-application.
What is the biggest threat to YCANTH sales?
The largest near-term threat is substitution by observation, procedures, or compounded cantharidin. The largest long-term threat is a generic topical product that obtains approval after the relevant exclusivity and patent barriers expire.
References
-
U.S. Food and Drug Administration. (2023). YCANTH (cantharidin) topical solution, 0.7%: Prescribing information and approval materials. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for Verrica Pharmaceuticals patent filings. USPTO.
-
U.S. Food and Drug Administration. (2024). ANDA submissions: Patent certification and 30-month stay provisions. FDA.
-
Verrica Pharmaceuticals Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.